American Shared Hospital Services (NYSE American: AMS), a provider of stereotactic radiosurgery equipment and advanced radiation therapy cancer treatment services, today announced it will hold a conference call to discuss its first quarter 2026 financial results on May 14, 2026, at 12:00 p.m. ET. The financial results press release will be issued before the market opens on the same day.
The call is significant as it provides investors and analysts an opportunity to assess the company's performance in the first quarter, including trends in its equipment leasing and direct patient care services segments. The company has been expanding its Gamma Knife, proton therapy, and advanced radiation therapy businesses, and the call may offer insights into the progress of these initiatives.
Interested parties can access the call by dialing 1-844-413-3972 (domestic) or 1-412-317-5776 (international) at least 10 minutes prior to the start time and asking to join the American Shared Hospital Services call. A simultaneous webcast will be available through the company's website at www.ashs.com or directly via the webcast link: https://event.choruscall.com/mediaframe/webcast.html?webcastid=NAuZg0I8A.
A telephonic replay of the call will be available from May 14 through May 21, 2026, by dialing 1-855-669-9658 or 1-412-317-0088 and entering access code 6753554. The webcast replay will also be accessible on the company's website.
American Shared Hospital Services provides turnkey solutions to cancer treatment centers, health systems, and cancer networks in North and South America. The company collaborates with partners to develop and grow cancer service lines, offering integrated cancer care in local settings. Under health system partnerships, the company and its partners share capital investment costs and profitability based on ownership interests.
Forward-looking statements in the announcement involve risks and uncertainties, including economic conditions, debt covenant compliance, quarterly financial variability, and factors related to the Gamma Knife, proton therapy, and advanced radiation therapy businesses. Detailed risk factors are available in the company's filings with the Securities and Exchange Commission, including the Annual Report on Form 10-K for the year ended December 31, 2025.
